.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,254,307

« Back to Dashboard

Details for Patent: 9,254,307

Title:Polymeric delivery formulations of leuprolide with improved efficacy
Abstract: The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.
Inventor(s): Dunn; Richard L. (Fort Collins, CO), Garrett; John Steven (Fort Collins, CO), Ravivarapu; Harish (Union City, CA), Chandrashekar; Bhagya L. (Fort Collins, CO)
Assignee: Tolmar Therapeutics, Inc. (Fort Collins, CO)
Filing Date:May 20, 2010
Application Number:12/784,343
Claims:1. A flowable composition suitable for use to form an in situ, single body controlled release implant, the composition consisting essentially of a non-aqueous, liquid solution of: (a) a biodegradable thermoplastic copolymer of lactide and glycolide that has a carboxy terminal group, that is at least substantially insoluble in aqueous medium or body fluid, and that has a weight average molecular weight of 15,000 to 45,000; (b) N-methyl-2-pyrrolidone; and (c) leuprolide acetate, wherein the copolymer is present in the composition at 30 wt % to 50 wt %; the N-methyl-2- pyrrolidone is present in the composition at 50 wt % to 70 wt % and the leuprolide acetate is present in the composition at 2 wt % to 8 wt %; and the composition is formulated for administration to a male patient about once per month to produce in situ the single body implant thereby reducing serum testosterone levels in the male patient.

2. A biodegradable implant formed in situ, in a male patient, by the steps comprising: (a) injecting 0.2 to 0.5 ml of the flowable composition of claim 1 within the body of the patient; and (b) allowing the N-methyl-2-pyrrolidone to dissipate to produce a solid, monolithic biodegradable implant of a microporous matrix of a core surrounded by a skin.

3. A method of reducing serum testosterone levels in a male human comprising injecting subcutaneously into the male human 0.2 ml to 0.5 ml of a flowable composition consisting essentially of a non-aqueous, liquid solution of: (a) a biodegradable thermoplastic copolymer of lactide and glycolide that has a carboxy terminal group, that is at least substantially insoluble in aqueous medium or body fluid, and that has a weight average molecular weight of 15,000 to 45,000; (b) N-methyl-2-pyrrolidone; and (c) leuprolide acetate in an amount sufficient to reduce LHRH levels in a human; wherein the copolymer is present in the composition at 30 wt % to 50 wt %; the N-methyl-2-pyrrolidone is present in the composition at 50 wt % to 70 wt % and the leuprolide acetate is present in the composition at 2 wt % to 8 wt %; whereupon the flowable composition forms in situ a monolithic solid implant of a microporous matrix of a core surrounded by a skin within a body tissue of the male human by diffusion of the N-methyl-2-pyrrolidone into the body fluid of the male human and precipitation of the copolymer of lactide and glycolide.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc